Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 14 Sep 2020

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.

Heavy periods, chronic hypertension in young women go hand in hand

04 Sep 2020

Heavy periods appear to have a bidirectional relationship with chronic hypertension among young women, such that the former is associated with subsequent risk of the latter and vice versa, according to a study.

Researchers looked at 7,729 women participating in the Australian Longitudinal Study on Women’s Health. The women documented their premenstrual syndrome, painful (dysmenorrhoea), heavy (menorrhagia), and irregular menstrual periods over the previous 12 months (recorded as never, rarely, sometimes, or often).

The participants also answered questions regarding physician-diagnosed hypertension, specifically for other than during pregnancy (characterized as chronic hypertension) and during pregnancy (hypertensive disorder in pregnancy [HDP]).

Over 15 years of follow-up, 757 women (9.8 percent) were diagnosed with chronic hypertension. Also, 483 of 4,473 parous women (10.8 percent) had HDP.

Generalized estimating equation time-lagged models revealed that women who often had heavy periods were at higher risk of developing chronic hypertension (relative risk [RR], 1.53, 95 percent confidence interval [CI], 1.13−2.09) compared with those who never had menorrhagia.

Moreover, chronic hypertension contributed to an increased risk of incident menorrhagia (RR, 1.23, 95 percent CI, 1.02−1.50) and irregular periods (RR, 1.42, 95 percent CI, 1.17−1.72).

No apparent association emerged between any menstrual symptoms and subsequent risk of HDP.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 14 Sep 2020

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.